Literature DB >> 1694461

RS 30026: a potent and effective calcium channel agonist.

L Patmore1, G P Duncan, B Clarke, A J Anderson, R Greenhouse, J R Pfister.   

Abstract

1. A series of dihydropyridine derivatives has been evaluated for calcium channel agonist activity using reversal of nisoldipine-induced inhibition of beating of aggregates of embryonic chick myocytes. This test appears to be specific for calcium channel agonists since isoprenaline and cardiac glycosides are inactive. 2. RS 30026 was the most potent of the series, was significantly more potent than CGP 28392 and of similar potency to Bay K 8644 (pEC50 = 7.45, 6.16 and 7.20, respectively). RS 30026 increased edge movement of individual aggregates, in the absence of nisoldipine, by 50% at 2 nM. 3. Compounds were also evaluated for their effects on guinea-pig papillary muscle and porcine coronary artery rings. RS 30026 displayed positive inotropism at concentrations between 10(-9) and 10(-6) M (pEC200 = 8.21), but was a much more powerful inotrope than Bay K 8644, increasing contractility to 1300% of control at 10(-6) M (compared to 350% of control for Bay K 8644). RS 30026 caused vasoconstriction at concentrations between 10(-10) and 10(-7) M. 4. Calcium channel currents in single embryonic chick myocytes were recorded by whole-cell voltage clamp techniques. RS 30026 (100 nM-500 nM) produced large increases in peak current amplitude and shifted the voltage for threshold and maximal currents to more negative values. RS 30026 (500 nM) also produced large increases in the inward tail currents evoked upon repolarization. The effects of Bay K 8644 (50 and 500 nM) were much less marked. 5. Analysis of the activation characteristics of currents showed parallel shifts in the activation curve to more negative potentials in the presence of 50 nm Bay K 8644, with a much smaller shift in the presence of 500nm Bay K 8644. RS 30026 (100 and 500nM) caused concentration-dependent shifts in the activation of the calcium channel currents with an increase of the slope of the curve. 6. RS 30026 appears to be the most potent and effective calcium channel agonist described to date.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1694461      PMCID: PMC1917534          DOI: 10.1111/j.1476-5381.1990.tb12990.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  Profile of the oppositely acting enantiomers of the dihydropyridine 202-791 in cardiac preparations: receptor binding, electrophysiological, and pharmacological studies.

Authors:  J S Williams; I L Grupp; G Grupp; P L Vaghy; L Dumont; A Schwartz; A Yatani; S Hamilton; A M Brown
Journal:  Biochem Biophys Res Commun       Date:  1985-08-30       Impact factor: 3.575

2.  The optical isomers of the 1,4-dihydropyridine BAY K 8644 show opposite effects on Ca channels.

Authors:  G Franckowiak; M Bechem; M Schramm; G Thomas
Journal:  Eur J Pharmacol       Date:  1985-08-15       Impact factor: 4.432

3.  Pharmacologic and radioligand binding analysis of the actions of 1,4-dihydropyridine activators related to Bay K 8644 in smooth muscle, cardiac muscle and neuronal preparations.

Authors:  Y W Kwon; G Franckowiak; D A Langs; M Hawthorn; A Joslyn; D J Triggle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989 Jan-Feb       Impact factor: 3.000

4.  Voltage- and use-dependent modulation of cardiac calcium channels by the dihydropyridine (+)-202-791.

Authors:  T J Kamp; M C Sanguinetti; R J Miller
Journal:  Circ Res       Date:  1989-02       Impact factor: 17.367

5.  Effects of calcium channel antagonists and facilitators on beating of primary cultures of embryonic chick heart cells.

Authors:  L Patmore; G P Duncan
Journal:  Br J Pharmacol       Date:  1988-11       Impact factor: 8.739

6.  The effects of calcium antagonists on calcium overload contractures in embryonic chick myocytes induced by ouabain and veratrine.

Authors:  L Patmore; G P Duncan; M Spedding
Journal:  Br J Pharmacol       Date:  1989-05       Impact factor: 8.739

7.  Interaction of palmitoyl carnitine with calcium antagonists in myocytes.

Authors:  L Patmore; G P Duncan; M Spedding
Journal:  Br J Pharmacol       Date:  1989-06       Impact factor: 8.739

8.  Stereoselectivity at the calcium channel: opposite action of the enantiomers of a 1,4-dihydropyridine.

Authors:  R P Hof; U T Rüegg; A Hof; A Vogel
Journal:  J Cardiovasc Pharmacol       Date:  1985 Jul-Aug       Impact factor: 3.105

9.  Opposing actions of the enantiomers of BAY-K-8644 on calcium currents and ACTH secretion in clonal pituitary corticotrophs.

Authors:  J F MacDonald; Z Miljkovic; S Heisler
Journal:  Can J Physiol Pharmacol       Date:  1987-12       Impact factor: 2.273

10.  Dual effects of dihydropyridines on whole cell and unitary calcium currents in single ventricular cells of guinea-pig.

Authors:  A M Brown; D L Kunze; A Yatani
Journal:  J Physiol       Date:  1986-10       Impact factor: 5.182

View more
  4 in total

1.  Mefenamic acid as a novel activator of L-type voltage-dependent Ca2+ channels in smooth muscle cells from pig proximal urethra.

Authors:  Noriyoshi Teramoto; Toshihisa Tomoda; Yushi Ito
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

2.  Quercetin as a novel activator of L-type Ca(2+) channels in rat tail artery smooth muscle cells.

Authors:  Simona Saponara; Giampietro Sgaragli; Fabio Fusi
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

3.  Kinetic modulation of guinea-pig cardiac L-type calcium channels by fendiline and reversal of the effects of Bay K 8644.

Authors:  W Schreibmayer; O Tripathi; H A Tritthart
Journal:  Br J Pharmacol       Date:  1992-05       Impact factor: 8.739

4.  4-Pyridinio-1,4-Dihydropyridines as Calcium Ion Transport Modulators: Antagonist, Agonist, and Dual Action.

Authors:  Ilona Domracheva; Iveta Kanepe-Lapsa; Reinis Vilskersts; Imanta Bruvere; Egils Bisenieks; Astrida Velena; Baiba Turovska; Gunars Duburs
Journal:  Oxid Med Cell Longev       Date:  2020-03-27       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.